TrialAmerican journal of hematology2019

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.

Elena Lukina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.